No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients

Molecular Oncology

Volumn 8, Issue 6, 2014, Pages 1140-1158

  Girotti, Maria Romina ^a   Saturno, Grazia ^a   Lorigan, Paul ^b   Marais, Richard ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Immunotherapy; Melanoma; Targeted therapy

Indexed keywords

B RAF KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROTEIN ANTIBODY; RAF PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; B RAF KINASE; PROTEIN KINASE INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; DIMERIZATION; HUMAN; IMMUNE RESPONSE; MELANOMA; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS;

EID: 84913539683     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.07.027     Document Type: Review

References (137)

1. Abdel-Wahab O., Klimek V.M., Gaskell A.A., Viale A., Cheng D., Kim E., Rampal R., Bluth M., Harding J.J., Callahan M.K., Merghoub T., Berger M.F., Solit D.B., Rosen N., Levine R.L., Chapman P.B. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov. 2014, 4:538-545.
2. Ackerman A., McDermott D., Lawrence D., Gunturi A., Flaherty K., Giobbie-Hurder A., Hodi F., Ibrahim N., Atkins M., Cho D., Sullivan R. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. 2012 ASCO Annual Meeting 2012.
3. Alwan L.M., Grossmann K., Sageser D., Van Atta J., Agarwal N., Gilreath J.A. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Targeted Oncol. 2014 Mar, 9(1):63-71.
4. Ascierto P.A., Simeone E., Sileni V.C., Vecchio M.D., Marchetti P., Cappellini G.C., Ridolfi R., de Rosa F., Cognetti F., Ferraresi V., Testori A., Queirolo P., Bernengo M.G., Guida M., Galli L., Mandala M., Cimminiello C., Rinaldi G., Carnevale-Schianca F., Maio M. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian Cohort of the ipilimumab expanded access program. Cancer Invest. 2014 May, 32(4):144-149.
5. Atefi M., von Euw E., Attar N., Ng C., Chu C., Guo D., Nazarian R., Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S., Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011, 6:e28973.
6. Atkins M.B., Kunkel L., Sznol M., Rosenberg S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 2000, 6(Suppl. 1):S11-S14.
7. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 1999, 17:2105-2116.
8. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S., Eggermont A.M., Flaherty K.T., Gimotty P.A., Kirkwood J.M., McMasters K.M., Mihm M.C., Morton D.L., Ross M.I., Sober A.J., Sondak V.K. Final version of 2009 AJCC melanoma staging and classification. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2009, 27:6199-6206.
9. Bhatia S., Tykodi S.S., Thompson J.A. Treatment of metastatic melanoma: an overview. Oncology 2009, 23:488-496.
10. Blasco R.B., Francoz S., Santamaria D., Canamero M., Dubus P., Charron J., Baccarini M., Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011, 19:652-663.
11. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K.Y., Artis D.R., Schlessinger J., Su F., Higgins B., Iyer R., D'Andrea K., Koehler A., Stumm M., Lin P.S., Lee R.J., Grippo J., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., Chapman P.B., Flaherty K.T., Xu X., Nathanson K.L., Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
12. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., Gilson M.M., Wang C., Selby M., Taube J.M., Anders R., Chen L., Korman A.J., Pardoll D.M., Lowy I., Topalian S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2010, 28:3167-3175.
13. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl. J. Med. 2012, 366:2455-2465.
14. Callahan M.K., Masters G., Pratilas C.A., Ariyan C., Katz J., Kitano S., Russell V., Gordon R.A., Vyas S., Yuan J., Gupta A., Wigginton J.M., Rosen N., Merghoub T., Jure-Kunkel M., Wolchok J.D. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol. Res. 2014, 2:70-79.
15. Callahan M.K., Rampal R., Harding J.J., Klimek V.M., Chung Y.R., Merghoub T., Wolchok J.D., Solit D.B., Rosen N., Abdel-Wahab O., Levine R.L., Chapman P.B. Progression of RAS-mutant leukemia during RAF inhibitor treatment. New Engl. J. Med. 2012, 367:2316-2321.
16. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Med. 2011, 364:2507-2516.
17. Chin L., Garraway L.A., Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006, 20:2149-2182.
18. Corcoran R.B., Rothenberg S.M., Hata A.N., Faber A.C., Piris A., Nazarian R.M., Brown R.D., Godfrey J.T., Winokur D., Walsh J., Mino-Kenudson M., Maheswaran S., Settleman J., Wargo J.A., Flaherty K.T., Haber D.A., Engelman J.A. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 2013, 5:196ra198.
19. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342:1432-1433.
20. Creagan E.T., Ahmann D.L., Frytak S., Long H.J., Chang M.N., Itri L.M. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat. Rep. 1986, 70:619-624.
21. Creagan E.T., Ahmann D.L., Frytak S., Long H.J., Itri L.M. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer 1986, 58:2576-2578.
22. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.H., Aiba S., Brocker E.B., LeBoit P.E., Pinkel D., Bastian B.C. Distinct sets of genetic alterations in melanoma. New Engl. J. Med. 2005, 353:2135-2147.
23. Das Thakur M., Salangsang F., Landman A.S., Sellers W.R., Pryer N.K., Levesque M.P., Dummer R., McMahon M., Stuart D.D. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494:251-255.
24. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
25. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., Lennon V.A., Celis E., Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
26. Dumaz N., Hayward R., Martin J., Ogilvie L., Hedley D., Curtin J.A., Bastian B.C., Springer C., Marais R. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006, 66:9483-9491.
27. Eggermont A.M., Kirkwood J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur. J. Cancer 2004, 40:1825-1836.
28. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., Gibbens I., Hackett S., James M., Schuchter L.M., Nathanson K.L., Xia C., Simantov R., Schwartz B., Poulin-Costello M., O'Dwyer P.J., Ratain M.J. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br. J. Cancer 2006, 95:581-586.
29. Emery C.M., Vijayendran K.G., Zipser M.C., Sawyer A.M., Niu L., Kim J.J., Hatton C., Chopra R., Oberholzer P.A., Karpova M.B., MacConaill L.E., Zhang J., Gray N.S., Sellers W.R., Dummer R., Garraway L.A. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20411-20416.
30. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., Hamid O., Infante J.R., Millward M., Pavlick A.C., O'Day S.J., Blackman S.C., Curtis C.M., Lebowitz P., Ma B., Ouellet D., Kefford R.F. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
31. Farrar M.A., Alberol-Ila J., Perlmutter R.M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature 1996, 383:178-181.
32. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49:1374-1403.
33. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Hamid O., Schuchter L., Cebon J., Ibrahim N., Kudchadkar R., Burris H.A., Falchook G., Algazi A., Lewis K., Long G.V., Puzanov I., Lebowitz P., Singh A., Little S., Sun P., Allred A., Ouellet D., Kim K.B., Patel K., Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl. J. Med. 2012, 367:1694-1703.
34. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl. J. Med. 2010, 363:809-819.
35. Flaherty K.T., Redlinger M., Schuchter L.M., Lathia C.D., Weber B.L., O'Dwyer P.J. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma, 2005 ASCO Annual Meeting. J.Clin. Oncol. 2005, 23. Asbtract 3037.
36. Freeman A.K., Ritt D.A., Morrison D.K. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cel. 2013, 49:751-758.
37. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J.Exp. Med. 2000, 192:1027-1034.
38. Gilmartin A.G., Bleam M.R., Groy A., Moss K.G., Minthorn E.A., Kulkarni S.G., Rominger C.M., Erskine S., Fisher K.E., Yang J., Zappacosta F., Annan R., Sutton D., Laquerre S.G. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained invivo pathway inhibition. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2011, 17:989-1000.
39. Girotti M.R., Marais R. Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov. 2013, 3:487-490.
40. Girotti M.R., Pedersen M., Sanchez-Laorden B., Viros A., Turajlic S., Niculescu-Duvaz D., Zambon A., Sinclair J., Hayes A., Gore M., Lorigan P., Springer C., Larkin J., Jorgensen C., Marais R. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2013, 3:158-167.
41. Goel V.K., Lazar A.J., Warneke C.L., Redston M.S., Haluska F.G. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J.Invest. Dermatol. 2006, 126:154-160.
42. Halaban R., Zhang W., Bacchiocchi A., Cheng E., Parisi F., Ariyan S., Krauthammer M., McCusker J.P., Kluger Y., Sznol M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cel. Melanoma Res. 2010, 23:190-200.
43. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl. J. Med. 2013, 369:134-144.
44. Hamid O., Sosman J., Lawrence D., Sullivan R., Ibrahim N., Kluger H., Boasberg P., Flaherty K., Hwu P., Ballinger M., Mokatrin A., Kowanetz M., Chen D., Hodi F. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). 2013 ASCO Annual Meeting. J.Clin. Oncol. 2013, 31. 2013 (suppl; abstr 9010).
45. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., Morales T., Aliagas I., Liu B., Sideris S., Hoeflich K.P., Jaiswal B.S., Seshagiri S., Koeppen H., Belvin M., Friedman L.S., Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
46. Hauschild A., Agarwala S.S., Trefzer U., Hogg D., Robert C., Hersey P., Eggermont A., Grabbe S., Gonzalez R., Gille J., Peschel C., Schadendorf D., Garbe C., O'Day S., Daud A., White J.M., Xia C., Patel K., Kirkwood J.M., Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2009, 27:2823-2830.
47. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., Martin-Algarra S., Karaszewska B., Mauch C., Chiarion-Sileni V., Martin A.M., Swann S., Haney P., Mirakhur B., Guckert M.E., Goodman V., Chapman P.B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
48. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
49. Hersh E.M., O'Day S.J., Powderly J., Khan K.D., Pavlick A.C., Cranmer L.D., Samlowski W.E., Nichol G.M., Yellin M.J., Weber J.S. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. New Drugs 2011, 29:489-498.
50. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003, 63:5198-5202.
51. Hino R., Kabashima K., Kato Y., Yagi H., Nakamura M., Honjo T., Okazaki T., Tokura Y. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116:1757-1766.
52. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M.T., Shankar S., Chen T.C., Korman A., Allison J.P., Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4712-4717.
53. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 2010, 363:711-723.
54. Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., Nickerson E., Auclair D., Li L., Place C., Dicara D., Ramos A.H., Lawrence M.S., Cibulskis K., Sivachenko A., Voet D., Saksena G., Stransky N., Onofrio R.C., Winckler W., Ardlie K., Wagle N., Wargo J., Chong K., Morton D.L., Stemke-Hale K., Chen G., Noble M., Meyerson M., Ladbury J.E., Davies M.A., Gershenwald J.E., Wagner S.N., Hoon D.S., Schadendorf D., Lander E.S., Gabriel S.B., Getz G., Garraway L.A., Chin L. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
55. Hoos A., Eggermont A.M., Janetzki S., Hodi F.S., Ibrahim R., Anderson A., Humphrey R., Blumenstein B., Old L., Wolchok J. Improved endpoints for cancer immunotherapy trials. J.Natl. Cancer Inst. 2010, 102:1388-1397.
56. Hu J., Stites E.C., Yu H., Germino E.A., Meharena H.S., Stork P.J., Kornev A.P., Taylor S.S., Shaw A.S. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 2013, 154:1036-1046.
57. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11:3887-3895.
58. Jang S., Atkins M.B. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin. Pharmacol. Ther. 2014, 95:24-31.
59. Jiang X., Zhou J., Giobbie-Hurder A., Wargo J., Hodi F.S. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2013, 19:598-609.
60. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., Caponigro G., Hieronymus H., Murray R.R., Salehi-Ashtiani K., Hill D.E., Vidal M., Zhao J.J., Yang X., Alkan O., Kim S., Harris J.L., Wilson C.J., Myer V.E., Finan P.M., Root D.E., Roberts T.M., Golub T., Flaherty K.T., Dummer R., Weber B.L., Sellers W.R., Schlegel R., Wargo J.A., Hahn W.C., Garraway L.A. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
61. Johnson D.B., Wallender E.K., Cohen D.N., Likhari S.S., Zwerner J.P., Powers J.G., Shinn L., Kelley M.C., Joseph R.W., Sosman J.A. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol. Res. 2013, 1:373.
62. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., Halilovic E., Persaud Y., Xing F., Viale A., Tsai J., Chapman P.B., Bollag G., Solit D.B., Rosen N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14903-14908.
63. Karasarides M., Chiloeches A., Hayward R., Niculescu-Duvaz D., Scanlon I., Friedlos F., Ogilvie L., Hedley D., Martin J., Marshall C.J., Springer C.J., Marais R. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
64. Karreth F.A., Frese K.K., DeNicola G.M., Baccarini M., Tuveson D.A. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 2011, 1:128-136.
65. Kaufman H.L., Kirkwood J.M., Hodi F.S., Agarwala S., Amatruda T., Bines S.D., Clark J.I., Curti B., Ernstoff M.S., Gajewski T., Gonzalez R., Hyde L.J., Lawson D., Lotze M., Lutzky J., Margolin K., McDermott D.F., Morton D., Pavlick A., Richards J.M., Sharfman W., Sondak V.K., Sosman J., Steel S., Tarhini A., Thompson J.A., Titze J., Urba W., White R., Atkins M.B. The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat. Rev. Clin. Oncol. 2013, 10:588-598.
66. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
67. Kim K.B., Kefford R., Pavlick A.C., Infante J.R., Ribas A., Sosman J.A., Fecher L.A., Millward M., McArthur G.A., Hwu P., Gonzalez R., Ott P.A., Long G.V., Gardner O.S., Ouellet D., Xu Y., DeMarini D.J., Le N.T., Patel K., Lewis K.D. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2013, 31:482-489.
68. Kirkwood J.M., Bastholt L., Robert C., Sosman J., Larkin J., Hersey P., Middleton M., Cantarini M., Zazulina V., Kemsley K., Dummer R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2012, 18:555-567.
69. Knight D.A., Ngiow S.F., Li M., Parmenter T., Mok S., Cass A., Haynes N.M., Kinross K., Yagita H., Koya R.C., Graeber T.G., Ribas A., McArthur G.A., Smyth M.J. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J.Clin. Invest. 2013, 123:1371-1381.
70. Kwong L.N., Costello J.C., Liu H., Jiang S., Helms T.L., Langsdorf A.E., Jakubosky D., Genovese G., Muller F.L., Jeong J.H., Bender R.P., Chu G.C., Flaherty K.T., Wargo J.A., Collins J.J., Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med. 2012, 18:1503-1510.
71. Laquerre S., Arnone M., Moss K., Yang J., Fisher K., Kane-Carson L.S., Smitheman K., Ward J., Heidrich B., Rheault T., Adjabeng G., Hornberger K., Stellwagen J., Waterson A., Han C., Mook R.A.J., Uehling D., King A.J. A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. AACR-NCI-EORTC International Conference. Molecular Cancer Therapeutics 2009, Abstract B88.
72. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., Greenfield E.A., Bourque K., Boussiotis V.A., Carter L.L., Carreno B.M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A.H., Freeman G.J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2:261-268.
73. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
74. Legha S.S., Ring S., Bedikian A., Plager C., Eton O., Buzaid A.C., Papadopoulos N. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 1996, 7:827-835.
75. Lipson E.J., Sharfman W.H., Drake C.G., Wollner I., Taube J.M., Anders R.A., Xu H., Yao S., Pons A., Chen L., Pardoll D.M., Brahmer J.R., Topalian S.L. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2013, 19:462-468.
76. Long G., Stroyakovsky D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J., Chiarion-Sileni V., Lebbe C., Mandalà M., Millward M., DeMarini D., Irani J., Le N., Casey M., Patel K., Flaherty K. COMBI-d: a randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J.Clin. Oncol. 2014, 32:5s. 2014 (suppl; abstr 9011).
77. Lorusso P.A., Krishnamurthi S.S., Rinehart J.J., Nabell L.M., Croghan G.A., Chapman P.B., Selaru P., Kim S., Ricart A.D., Wilner K.D. Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2007.
78. Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., Hanson L., DeLuca P., Bruzek L., Piens J., Asbury P., Van Becelaere K., Herrera R., Sebolt-Leopold J., Meyer M.B. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2005, 23:5281-5293.
79. Lui P., Cashin R., Machado M., Hemels M., Corey-Lisle P.K., Einarson T.R. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat. Rev. 2007, 33:665-680.
80. Luo Z., Tzivion G., Belshaw P.J., Vavvas D., Marshall M., Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 1996, 383:181-185.
81. Lutzky J., Antonia S., Blake-Haskins A., Li X., Robbins P., Shalabi A., Vasselli J., Ibrahim R., Khleif S., Segal N. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors., 2014 ASCO Annual Meeting. J.Clin. Oncol. 2014, 32:5s. 2014 (suppl; abstr 3001).
82. Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr.-Relat. Cancer 2001, 8:219-225.
83. Madhunapantula S.V., Robertson G.P. Is B-Raf a good therapeutic target for melanoma and other malignancies?. Cancer Res. 2008, 68:5-8.
84. Marusiak A.A., Edwards Z.C., Hugo W., Trotter E.W., Girotti M.R., Stephenson N.L., Kong X., Gartside M.G., Fawdar S., Hudson A., Breitwieser W., Hayward N.K., Marais R., Lo R.S., Brognard J. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nat. Commun. 2014, 5:3901.
85. Mattei P.L., Alora-Palli M.B., Kraft S., Lawrence D.P., Flaherty K.T., Kimball A.B. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2013, 24:530-537.
86. McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P.A., Garbe C., Testori A., Maio M., Lorigan P., Lebbe C., Jouary T., Schadendorf D., O'Day S.J., Kirkwood J.M., Eggermont A.M., Dreno B., Sosman J.A., Flaherty K.T., Yin M., Caro I., Cheng S., Trunzer K., Hauschild A. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014, 15:323-332.
87. Meier F., Schittek B., Busch S., Garbe C., Smalley K., Satyamoorthy K., Li G., Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. : A J. Virtual Libr. 2005, 10:2986-3001.
88. Melero I., Grimaldi A.M., Perez-Gracia J.L., Ascierto P.A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2013, 19:997-1008.
89. Middleton M.R., Grob J.J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S., Gore M., Aamdal S., Cebon J., Coates A., Dreno B., Henz M., Schadendorf D., Kapp A., Weiss J., Fraass U., Statkevich P., Muller M., Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2000, 18:158-166.
90. Montagut C., Sharma S.V., Shioda T., McDermott U., Ulman M., Ulkus L.E., Dias-Santagata D., Stubbs H., Lee D.Y., Singh A., Drew L., Haber D.A., Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008, 68:4853-4861.
91. Morris E.J., Jha S., Restaino C.R., Dayananth P., Zhu H., Cooper A., Carr D., Deng Y., Jin W., Black S., Long B., Liu J., Dinunzio E., Windsor W., Zhang R., Zhao S., Angagaw M.H., Pinheiro E.M., Desai J., Xiao L., Shipps G., Hruza A., Wang J., Kelly J., Paliwal S., Gao X., Babu B.S., Zhu L., Daublain P., Zhang L., Lutterbach B.A., Pelletier M.R., Philippar U., Siliphaivanh P., Witter D., Kirschmeier P., Bishop W.R., Hicklin D., Gilliland D.G., Jayaraman L., Zawel L., Fawell S., Samatar A.A. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013, 3:742-750.
92. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., Chodon T., Nelson S.F., McArthur G., Sosman J.A., Ribas A., Lo R.S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
93. Nikolaev S.I., Rimoldi D., Iseli C., Valsesia A., Robyr D., Gehrig C., Harshman K., Guipponi M., Bukach O., Zoete V., Michielin O., Muehlethaler K., Speiser D., Beckmann J.S., Xenarios I., Halazonetis T.D., Jongeneel C.V., Stevenson B.J., Antonarakis S.E. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 2012, 44:133-139.
94. Oberholzer P.A., Kee D., Dziunycz P., Sucker A., Kamsukom N., Jones R., Roden C., Chalk C.J., Ardlie K., Palescandolo E., Piris A., MacConaill L.E., Robert C., Hofbauer G.F., McArthur G.A., Schadendorf D., Garraway L.A. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2012, 30:316-321.
95. Paraiso K.H., Fedorenko I.V., Cantini L.P., Munko A.C., Hall M., Sondak V.K., Messina J.L., Flaherty K.T., Smalley K.S. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 2010, 102:1724-1730.
96. Paraiso K.H., Xiang Y., Rebecca V.W., Abel E.V., Chen Y.A., Munko A.C., Wood E., Fedorenko I.V., Sondak V.K., Anderson A.R., Ribas A., Palma M.D., Nathanson K.L., Koomen J.M., Messina J.L., Smalley K.S. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011, 71:2750-2760.
97. Payne M.J., Argyropoulou K., Lorigan P., McAleer J.J., Farrugia D., Davidson N., Kelly C., Chao D., Marshall E., Han C., Wellman S., Middleton M.R. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2014, 32:185-190.
98. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M.T., Salton M., Dahlman K.B., Tadi M., Wargo J.A., Flaherty K.T., Kelley M.C., Misteli T., Chapman P.B., Sosman J.A., Graeber T.G., Ribas A., Lo R.S., Rosen N., Solit D.B. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
99. Powderly J., Koeppen H., Hodi F., Sosman J., Gettinger S., Desai R., Tabernero J., Soria J., Hamid O., Fine G., Xiao Y., Mokatrin A., Wu J., Anderson M., Irving B., Chen D., Kowanetz M. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study., 2013 ASCO Annual Meeting. J.Clin. Oncol. 2013, 31. 2013 (suppl; abstr 3001).
100. Prickett T.D., Agrawal N.S., Wei X., Yates K.E., Lin J.C., Wunderlich J.R., Cronin J.C., Cruz P., Rosenberg S.A., Samuels Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 2009, 41:1127-1132.
101. Puzanov I., Callahan M., Linette G., Patel S., Luke J., Sosman J., Wolchok J., Hamid O., Minor D., Orford K., Hug B., Ma B., Matthys G., Hoos A. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). 2014 ASCO Annual Meeting. J.Clin. Oncol. 2014, 32:5s. 2014 (suppl; abstr 2511).
102. Rebocho A.P., Marais R. ARAF acts as a scaffold to stabilize BRAF: CRAF heterodimers. Oncogene 2013, 32:3207-3212.
103. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin. Oncol. 2010, 37:450-454.
104. Ribas A., Hodi F.S., Callahan M., Konto C., Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. New Engl. J. Med. 2013, 368:1365-1366.
105. Ribas A., Hodi S., Kefford R., Hamid O., Daud A., Wolchok J., Hwu W., Gangadhar T., Patnaik A., Joshua A., Hersey P., Weber J., Dronca R., Zarour H., Gergich K., Li X., Iannone R., Kang S., Ebbinghaus S., Robert C., D., G Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). 2014 ASCO Annual Meeting. J.Clin. Oncol. 2014, 32:5s. LBA9000.
106. Robert C., Thomas L., Bondarenko I., O'Day S., J, Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., Davidson N., Richards J., Maio M., Hauschild A., Miller W.H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.T., Humphrey R., Hoos A., Wolchok J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl. J. Med. 2011, 364:2517-2526.
107. Schadendorf D., Hodi F., Robert C. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma., LBA24. Eur. Cancer Congress 2013.
108. Schwartz G.K., Robertson S., Shen A., Wang E., Pace L., Dials H., Mendelson D., Shannon P., Gordon M. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors., 2009 ASCO Annual Meeting. J.Clin. Oncol. 2009, 27:15s. Abstract 3513.
109. Sharfman W.H., Hodi F.S., Lawrence D.P., Flaherty K.T., Amaravadi R.K., Kim K.B., Dummer R., Gobbi S., Puzanov I., Sosman J.A., Dohoney K., Lam L.P., Kakar S., Tang Z., Krieter O., Atkins M.B. Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. 2011 ASCO Annual Meeting. J.Clin. Oncol. 2011, 29. 2011 (suppl; abstr 8508).
110. Shi H., Hong A., Kong X., Koya R.C., Song C., Moriceau G., Hugo W., Yu C.C., Ng C., Chodon T., Scolyer R.A., Kefford R.F., Ribas A., Long G.V., Lo R.S. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014, 4:69-79.
111. Shi H., Hugo W., Kong X., Hong A., Koya R.C., Moriceau G., Chodon T., Guo R., Johnson D.B., Dahlman K.B., Kelley M.C., Kefford R.F., Chmielowski B., Glaspy J.A., Sosman J.A., van Baren N., Long G.V., Ribas A., Lo R.S. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014, 4:80-93.
112. Shi H., Kong X., Ribas A., Lo R.S. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011, 71:5067-5074.
113. Shi H., Moriceau G., Kong X., Koya R.C., Nazarian R., Pupo G.M., Bacchiocchi A., Dahlman K.B., Chmielowski B., Sosman J.A., Halaban R., Kefford R.F., Long G.V., Ribas A., Lo R.S. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012, 2:414-424.
114. Shi H., Moriceau G., Kong X., Lee M.K., Lee H., Koya R.C., Ng C., Chodon T., Scolyer R.A., Dahlman K.B., Sosman J.A., Kefford R.F., Long G.V., Nelson S.F., Ribas A., Lo R.S. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 2012, 3:724.
115. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA: A Cancer J. Clin. 2014, 64:9-29.
116. Slipicevic A., Holm R., Nguyen M.T., Bohler P.J., Davidson B., Florenes V.A. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am. J. Clin. Pathol. 2005, 124:528-536.
117. Smalley K.S., Aplin A.E., Flaherty K.T., Hoeller C., Bosserhoff A.K., Haass N.K., Bosenberg M., Ribas A., Barnhill R., Kudchadkar R., Messina J.L. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cel. Melanoma Res. 2012, 25:E1-E11.
118. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., Hersey P., Kefford R., Lawrence D., Puzanov I., Lewis K.D., Amaravadi R.K., Chmielowski B., Lawrence H.J., Shyr Y., Ye F., Li J., Nolop K.B., Lee R.J., Joe A.K., Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New Engl. J. Med. 2012, 366:707-714.
119. Sosman J.A., Kittaneh M., Lolkema M.P.J.K., Postow M.A., Schwartz G., Franklin C., Matano A., Bhansali S., Parasuraman S., K K. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. 2014 ASCO Annual Meeting 2014.
120. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., Cooper Z.A., Chapman P.B., Solit D.B., Ribas A., Lo R.S., Flaherty K.T., Ogino S., Wargo J.A., Golub T.R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487(7408):500-504.
121. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., Reis-Filho J.S., Kong X., Koya R.C., Flaherty K.T., Chapman P.B., Kim M.J., Hayward R., Martin M., Yang H., Wang Q., Hilton H., Hang J.S., Noe J., Lambros M., Geyer F., Dhomen N., Niculescu-Duvaz I., Zambon A., Niculescu-Duvaz D., Preece N., Robert L., Otte N.J., Mok S., Kee D., Ma Y., Zhang C., Habets G., Burton E.A., Wong B., Nguyen H., Kockx M., Andries L., Lestini B., Nolop K.B., Lee R.J., Joe A.K., Troy J.L., Gonzalez R., Hutson T.E., Puzanov I., Chmielowski B., Springer C.J., McArthur G.A., Sosman J.A., Lo R.S., Ribas A., Marais R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. New Engl. J. Med. 2012, 366:207-215.
122. Sun C., Wang L., Huang S., Heynen G.J., Prahallad A., Robert C., Haanen J., Blank C., Wesseling J., Willems S.M., Zecchin D., Hobor S., Bajpe P.K., Lieftink C., Mateus C., Vagner S., Grernrum W., Hofland I., Schlicker A., Wessels L.F., Beijersbergen R.L., Bardelli A., Di Nicolantonio F., Eggermont A.M., Bernards R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508:118-122.
123. Sznol M., Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2013, 19:5542.
124. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997, 7:445-450.
125. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl. J. Med. 2012, 366:2443-2454.
126. Trunzer K., Pavlick A.C., Schuchter L., Gonzalez R., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., Kim K.B., Weber J.S., Hersey P., Long G.V., Lawrence D., Ott P.A., Amaravadi R.K., Lewis K.D., Puzanov I., Lo R.S., Koehler A., Kockx M., Spleiss O., Schell-Steven A., Gilbert H.N., Cockey L., Bollag G., Lee R.J., Joe A.K., Sosman J.A., Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2013, 31:1767-1774.
127. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3041-3046.
128. Tseng S.Y., Otsuji M., Gorski K., Huang X., Slansky J.E., Pai S.I., Shalabi A., Shin T., Pardoll D.M., Tsuchiya H. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J.Exp. Med. 2001, 193:839-846.
129. Turajlic S., Furney S.J., Stamp G., Rana S., Ricken G., Oduko Y., Saturno G., Springer C., Hayes A., Gore M., Larkin J., Marais R. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2014, 25(5):959-967.
130. Van Allen E.M., Wagle N., Sucker A., Treacy D.J., Johannessen C.M., Goetz E.M., Place C.S., Taylor-Weiner A., Whittaker S., Kryukov G.V., Hodis E., Rosenberg M., McKenna A., Cibulskis K., Farlow D., Zimmer L., Hillen U., Gutzmer R., Goldinger S.M., Ugurel S., Gogas H.J., Egberts F., Berking C., Trefzer U., Loquai C., Weide B., Hassel J.C., Gabriel S.B., Carter S.L., Getz G., Garraway L.A., Schadendorf D. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2013 Jan, 4(1):94-109. on behalf of the Dermatologic Cooperative Oncology Group of, G.
131. Vergani E., Vallacchi V., Frigerio S., Deho P., Mondellini P., Perego P., Cassinelli G., Lanzi C., Testi M.A., Rivoltini L., Bongarzone I., Rodolfo M. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 2011, 13:1132-1142.
132. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Brown K.D., Laquerre S., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
133. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
134. Weber J.S., Kudchadkar R.R., Yu B., Gallenstein D., Horak C.E., Inzunza H.D., Zhao X., Martinez A.J., Wang W., Gibney G., Kroeger J., Eysmans C., Sarnaik A.A., Chen Y.A. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J.Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2013, 31:4311-4318.
135. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., Ribas A., Li J., Moffat J., Sutherlin D.P., Koeppen H., Merchant M., Neve R., Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487(7408):505-509.
136. Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbe C., Maio M., Binder M., Bohnsack O., Nichol G., Humphrey R., Hodi F.S. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15:7412-7420.
137. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., Burke M.M., Caldwell A., Kronenberg S.A., Agunwamba B.U., Zhang X., Lowy I., Inzunza H.D., Feely W., Horak C.E., Hong Q., Korman A.J., Wigginton J.M., Gupta A., Sznol M. Nivolumab plus ipilimumab in advanced melanoma. New Engl. J. Med. 2013, 369:122-133.